Literature DB >> 14971638

Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression.

T G Dinan1, S O'Brien, E Lavelle, L V Scott.   

Abstract

BACKGROUND: In situations of chronic stress vasopressin plays an important role in regulating the hypothalamic-pituitary adrenal axis. The aim of the current study was to investigate the role of anterior pituitary vasopressin V3 receptors in maintaining the hypercortisolism seen in melancholic depression.
METHOD: Fourteen patients with major depression and 14 age- and sex-matched healthy comparison subjects were recruited. Desmopressin (ddAVP) 10 microg was given intravenously and ACTH and cortisol release was monitored for 120 min.
RESULTS: The mean +/- S.E.M. ACTH response in the depressives was 28.4 +/- 4.3 ng/l and in the healthy subjects was 18.8 +/- 4.9 ng/l (P = 0.04). The mean +/- S.E.M. cortisol response in the depressives was 261.8 +/- 46.5 nmol/l and in the healthy subjects was 107.3 +/- 26.1 nmol/l (P < 0.01).
CONCLUSIONS: Patients with major depression have augmented ACTH and cortisol responses to desmopressin indicating enhanced V3 responsivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971638     DOI: 10.1017/s0033291703001004

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  9 in total

Review 1.  Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin.

Authors:  Timothy G Dinan; Lucinda V Scott
Journal:  J Anat       Date:  2005-09       Impact factor: 2.610

2.  Plasma oxytocin and vasopressin levels in young and older men and women: Functional relationships with attachment and cognition.

Authors:  Gabriela Plasencia; Joerg M Luedicke; Hossein P Nazarloo; C Sue Carter; Natalie C Ebner
Journal:  Psychoneuroendocrinology       Date:  2019-08-31       Impact factor: 4.905

Review 3.  Cognition in mania and depression: psychological models and clinical implications.

Authors:  Samuel R Chamberlain; Barbara J Sahakian
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

Review 4.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

5.  Familial and temperamental predictors of resilience in children at risk for conduct disorder and depression.

Authors:  Katherine E Shannon; Theodore P Beauchaine; Sharon L Brenner; Emily Neuhaus; Lisa Gatzke-Kopp
Journal:  Dev Psychopathol       Date:  2007

Review 6.  Vasopressin: behavioral roles of an "original" neuropeptide.

Authors:  Heather K Caldwell; Heon-Jin Lee; Abbe H Macbeth; W Scott Young
Journal:  Prog Neurobiol       Date:  2007-11-04       Impact factor: 11.685

Review 7.  Cortisol and Major Depressive Disorder-Translating Findings From Humans to Animal Models and Back.

Authors:  L Sanjay Nandam; Matthew Brazel; Mei Zhou; Dhanisha J Jhaveri
Journal:  Front Psychiatry       Date:  2020-01-22       Impact factor: 4.157

Review 8.  Vasopressin V1B Receptor Antagonists as Potential Antidepressants.

Authors:  Shigeyuki Chaki
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

9.  Early response to venlafaxine antidepressant correlates with lower ACTH levels prior to pharmacological treatment.

Authors:  A V Araya; P Rojas; R Fritsch; R Rojas; L Herrera; G Rojas; H Gatica; H Silva; J L Fiedler
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.